

1262678

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

December 16, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

**APPLICATION NUMBER: 60/525,502
FILING DATE: November 26, 2003
RELATED PCT APPLICATION NUMBER: PCT/US04/39391**

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office

BEST AVAILABLE COPY

Please type a plus sign (+) inside this box → ☐

PTO/SB/16 (8-00)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

22388 U.S. PTO
60/525502



INVENTOR(S)					
Given Name (first and middle (if any))		Family Name or Surname		Residence (City and either State or Foreign Country)	
Qunmin Yang		Zhou Liu		Powell, Ohio U.S. Columbus, Ohio U.S.	
<input checked="" type="checkbox"/> Additional inventors are being named on the 2nd separately numbered sheets attached hereto					
TITLE OF THE INVENTION (280 characters max)					
POLYMORPHIC CD24 GENOTYPES THAT ARE PREDICTIVE OF MULTIPLE SCLEROSIS RISK AND PROGRESSION					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number		24024		→ Place Customer Number Bar Code Label here	
OR Type Customer Number here					
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		ZIP	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification		Number of Pages		39	
<input checked="" type="checkbox"/> Drawing(s)		Number of Sheets		6	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		<input type="checkbox"/> CD(s), Number			
		<input checked="" type="checkbox"/> Other (specify)		Return Receipt Postcard	
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)	
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:		03-0172		\$80.00	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME Diane H. Dobrea

TELEPHONE (215) 622-8200

Date 11 / 26 / 03

REGISTRATION NO.
(if appropriate)
Docket Number:

48,578

22727/04200

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (8-00)

Approved for use through 10/31/2002. OMB 0651-0032
Trademark Office U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Docket Number	22727/04200	Type a plus sign (+) inside this box →	+
INVENTOR(S)/APPLICANT(S)					
Given Name (first and middle (if any))		Family or Surname	Residence (City and either State or Foreign Country)		
Pan		Zheng	Columbus, Ohio U.S.		
Kotil		Rammohan	Columbus, Ohio U.S.		
Shili		Lin	Columbus, Ohio U.S.		

Number 2 of 2

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	Unknown	
	Filing Date	November 26, 2003	
	First Named Inventor	Zhou	
	Art Unit	Unknown	
	Examiner Name	Unknown	
Total Number of Pages in This Submission	49	Attorney Docket Number	22727/04200

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks Transmittal form (1 page) Provisional Patent Cover Sheet (2 pages); Provisional Specification (39 pages); Drawings (6 pages); Check in the amount of \$80.00; and Return receipt postcard		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Diane H. Dobrea - Calfee, Halter & Griswold LLP (Reg. No. 48,578) Customer No. 24024
Signature	<i>[Signature]</i>
Date	November 26, 2003

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. <i>Express Mailing Label No. E108475206945</i>		
Typed or printed name	ROBERT WATTS	
Signature	<i>Robert Watts</i>	Date 11-26-2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL
for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$ 80.00)

C mplete if Known

Application Number	Unknown
Filing Date	November 26, 2003
First Named Inventor	Zhou
Examiner Name	Unknown
Art Unit	Unknown
Attorney Docket No.	22727/04200

METHOD OF PAYMENT (check all that apply)☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit
Account
Number
Deposit
Account
Name

03-0172

CALFEE, HALTER & GRISWOLD

The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) during the pendency of this application☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 750	2001 375	Utility filing fee	
1002 330	2002 165	Design filing fee	
1003 520	2003 260	Plant filing fee	
1004 750	2004 375	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	80.00

SUBTOTAL (1) (\$ 80.00)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	X	
Multiple Dependent Claims	-3** =	X	

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 84	2201 42	Independent claims in excess of 3
1203 280	2203 140	Multiple dependent claim, if not paid
1204 84	2204 42	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 0)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 410	2252 205	Extension for reply within second month	
1253 930	2253 465	Extension for reply within third month	
1254 1,450	2254 725	Extension for reply within fourth month	
1255 1,970	2255 985	Extension for reply within fifth month	
1401 320	2401 160	Notice of Appeal	
1402 320	2402 160	Filing a brief in support of an appeal	
1403 280	2403 140	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,300	2453 650	Petition to revive - unintentional	
1501 1,300	2501 650	Utility issue fee (or reissue)	
1502 470	2502 235	Design issue fee	
1503 630	2503 315	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 750	2809 375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 750	2810 375	For each additional invention to be examined (37 CFR 1.129(b))	
1801 750	2801 375	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0)

SUBMITTED BY

(Complete if applicable)

Name (Print/Type)	Diane H. Dobrea	Registration No. (Attorney/Agent)	48,578	Telephone	216-622-8200
Signature		Date	November 26, 2003		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

EXPRESS MAILING CERTIFICATE"EXPRESS MAIL" Mailing Label No.: **EL084752069US**Date of Deposit: November 26, 2003

I hereby certify that this application is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Typed or printed name of person signing this certificate:

ROBERT WATTSSigned: Robert Watts**PATENT**

**POLYMORPHIC CD24 GENOTYPES THAT ARE
PREDICTIVE OF MULTIPLE SCLEROSIS RISK AND PROGRESSION**

5

This invention was supported, at least in part, by NCI grant CA90223. The Federal Government has certain rights in this invention.

FIELD OF THE INVENTION

The invention relates to genetic analysis of CD24 gene for predicting risk and progression of multiple sclerosis and for designing differential treatment of multiple sclerosis depending on the allotype of the CD24 gene.

10

Background

15

20

Multiple sclerosis (MS) is a chronic inflammatory disorder in the central nervous system (CNS) that affects approximately 0.1% of Caucasians of Northern European origin (1) (approximately 250,000 individuals in the United States). The incidence of MS is increased among family members of affected individuals. The concordance rate of the identical twins can be as high as 30% (1) (2, 3). Although the clinical course may be quite variable, the most common form of MS is manifested by relapsing neurological deficits, in particular, paralysis, sensory deficits, and visual problems. The inflammatory process occurs primarily within the white matter of the central nervous system and is mediated by T lymphocytes, B lymphocytes,

and macrophages. These cells are responsible for the demyelination of axons. The characteristic lesion in MS is called the plaque. Multiple sclerosis is thought to arise from pathogenic T cells that somehow evaded mechanisms establishing self-tolerance, and attack normal tissue. T cell reactivity to myelin basic protein may be a critical component in the development of MS.

5 An individual with clinically definite MS has had two attacks and has presented with clinical evidence of either two lesions or clinical evidence of one lesion and paraclinical evidence of another, separate lesion. Definite MS may also be diagnosed by evidence of two attacks and oligoclonal bands of IgG in cerebrospinal fluid or by combination of an attack, clinical evidence of two lesions and oligoclonal band of IgG in cerebrospinal fluid. Slightly
10 lower criteria are used for a diagnosis of clinically probable MS. Clinical progression of multiple sclerosis may be examined in several different ways. Three main criteria are used: EDSS (extended disability status scale), appearance of exacerbations or MRI (magnetic resonance imaging).

The EDSS is a means to grade clinical impairment due to MS (Kurtzke, Neurology
15 33:1444, 1983). Eight functional systems are evaluated for the type and severity of neurologic impairment. Prior to treatment, patients are evaluated for impairment in the following systems: pyramidal, cerebella, brainstem, sensory, bowel and bladder, visual, cerebral, and other. Follow-ups are conducted at defined intervals. The scale ranges from 0 (normal) to 10 (death due to MS). A decrease of one full step defines an effective treatment in the context of the present
20 invention (Kurtzke, Ann. Neurol. 36:573-79, 1994).

MRI can be used to measure active lesions using gadolinium-DTPA-enhanced imaging (McDonald et al. Ann. Neurol. 36:14, 1994) or the location and extent of lesions using T₂ - weighted techniques. Baseline MRIs are obtained. The same imaging plane and patient position

are used for each subsequent study. Positioning and imaging sequences are chosen to maximize lesion detection and facilitate lesion tracing. The same positioning and imaging sequences are used on subsequent studies. The presence, location and extent of MS lesions are determined by radiologists. Areas of lesions are outlined and summed slice by slice for total lesion area. Three analyses may be done: evidence of new lesions, rate of appearance of active lesions, percentage change in lesion area (Paty et al., *Neurology* 43:665, 1993).

No curative treatment for MS has been established. Corticosteroids and ACTH have been used to treat MS. Basically, these drugs reduce the inflammatory response by toxicity to lymphocytes. Recovery may be hastened from acute exacerbations, but these drugs do not prevent future attacks or prevent development of additional disabilities or chronic progression of MS (Carter and Rodriguez, *Mayo Clinic Proc.* 64:664, 1989; Weiner and Hafler, *Ann. Neurol.* 23:211, 1988). Other toxic compounds, such as azathioprine, a purine antagonist, cyclophosphamide, and cyclosporine have been used to treat symptoms of MS. As with corticosteroid treatment, these drugs are beneficial at most for a short term and are highly toxic. Side effects include increased-malignancies, leukopenias, toxic hepatitis, gastrointestinal problems, hypertension, and nephrotoxicity (Mitchell, *Cont. Clin. Neurol.* 77:231, 1993; Weiner and Hafler, *siipra*). Antibody based therapies directed toward T cells, such as anti-CD4 antibodies, and anti-CD24 antibodies may also be useful, though these agents may cause deleterious side effects by immunocompromising the patient. Several forms of beta interferon have been approved for use in MS patients.

The HLA locus is perhaps an important genetic element for MS susceptibility, as the HLA-DR2 allele has been identified as an most important susceptibility gene among Caucasians (4-10). A majority of MS patients have HLA-type DR2a and DR2b. In addition, several

additional loci have been proposed (8-12). Whole genome scanning has suggested a linkage-disequilibrium in the distal region of chromosome 6q (8), whose identity has not been revealed. An interesting candidate in the region is CD24 (13). We have previously shown that expression of CD24 is essential for the induction of experimental autoimmune encephalomyelitis (EAE) in mice (13).

CD24 is a glycosylphosphatidyl-inositol (GPI)-anchored cell surface protein with expression in a variety of cell types that can participate in the pathogenesis of MS, including activated T cells (14, 15), B cells (16), macrophages (17), dendritic cells (18), and local antigen-presenting cells in the CNS, such as vascular endothelial cells, astrocytes, and microglia (our unpublished observation). It is well established that in the mouse CD24 mediates a CD28-independent co-stimulatory pathway that promotes activation of CD4 and CD8 T cells (16-21). In addition, CD24 has been shown to modulate the VLA4-fibronectin/VCAM-1 interaction (22), which is required for the migration of T cells to the CNS, and therefore the development of EAE in the mouse (23). We have recently demonstrated that CD24 is required for the development of EAE in the mouse (13). Interestingly, CD24 controls a checkpoint of EAE pathogenesis after the autoreactive T cells are produced (13).

Despite what is known about MS, the methods available to predict an individual's likelihood of developing MS remain inadequate. Likewise, no generally accepted methods are available to predict the aggressiveness of MS in patients that have been diagnosed with the disease. Accordingly, it would be desirable to have methods for screening the genetic profiles of individuals who are at risk for MS or known to have MS so as to better predict the development and course of disease in such individuals, and to customize treatment based on an individual's genetic profile.

Summary of the Invention

As described herein, it has been discovered that the presence of a single-nucleotide polymorphism (SNP) in the human CD24 gene is correlated with risk for developing MS, and with the rate of progression of the disease in patients diagnosed with MS. In particular, it has been discovered that the presence of a SNP within the nucleotide sequence encoding the CD24 gene product is positively correlated with increased incidence and more rapid progression of MS in a sample population assessed as described herein. As used herein in reference to MS, the term “rapid progression” means that an individual has reached or will reach EDSS 6.0 within 5 to 8 years from the time of first diagnosis of MS.

In one embodiment, a single nucleotide polymorphism from C (cytosine) to T (thymidine) at nucleotide position 226 in exon 2 of the coding sequence of the CD24 gene, resulting in an amino acid change from A (alanine) to V (valine) at amino acid position -1 (relative to the cleavage site of the mature, membrane-inserted protein), is positively correlated with an increased risk for developing MS and with more rapid progression of MS in the sample population assessed as described herein. The wild-type allele at position 226 is designated herein as “*CD24*^{226a}” and the variant allele is designated herein as “*CD24*^{226v}”. This particular polymorphism may be one of a group of two or more polymorphisms in the CD24 gene, or linked genes, which contributes to the development and progression of MS. As used herein in connection with the nucleotide at position 226 and the corresponding amino acid in CD24, the term “wild-type” refers to the allele for alanine and the term “variant” refers to an allele that differs or varies from the wild-type allele, such as the allele for valine which is described herein. Use of the terms wild-type and variant is merely for convention, and is not intended to suggest that either allelic form is a mutant of the other.

A wild-type or variant allele, such as either *CD24*^{226a} or *CD24*^{226v}, can be detected by any of a variety of available techniques, including: 1) performing a hybridization reaction between a nucleic acid sample and a probe that is capable of hybridizing to the allele; 2) sequencing at least a portion of the allele; or 3) determining the electrophoretic mobility of the allele or fragments thereof (e.g., fragments are generated by endonuclease digestion, then analyzed by a technique such as RFLP). The allele can optionally be subjected to an amplification step prior to performance of the detection step. Preferred amplification methods are selected from the group consisting of: the polymerase chain reaction (PCR), the ligase chain reaction (LCR), strand displacement amplification (SDA), cloning, and variations of the above (e.g. RT-PCR and allele specific amplification). Oligonucleotide primers that are directed to target sequences upstream and downstream of nucleotide position 226 and necessary for amplification may be selected for example, from within the *CD24* gene, either flanking the SNP location, for example nucleotide position 226 (as required for PCR amplification), or directly overlapping the SNP location, for example nucleotide position 226 (as in ASO hybridization). In a particularly preferred embodiment, the sample is hybridized with a set of primers, which hybridize 5' and 3' in a sense or antisense sequence to the SNP, and is subjected to a PCR amplification.

An allele may also be detected indirectly, e.g. by analyzing the protein product encoded by the DNA. For example, where the marker in question results in the translation of a mutant protein, the protein can be detected by any of a variety of protein detection methods. Such methods include immunodetection and biochemical tests, such as size fractionation, where the protein has a change in apparent molecular weight either through truncation, elongation, altered folding or altered post-translational modifications. In a particularly preferred embodiment, the

level of expression of the protein is evaluated based on the presence of the protein on the surface of cells, preferably peripheral blood lymphocytes, and most preferably T cells.

In one embodiment, the invention relates to a method for predicting the likelihood that an individual will have or develop MS, or that an individual who has been diagnosed with MS will
5 experience more rapid progression of the disease, comprising the steps of obtaining a polynucleotide sample from an individual to be assessed and determining the nucleotide present at nucleotide position 226 of the CD24 gene. The presence of a "T" (the variant nucleotide) at position 226 indicates that the individual has a greater likelihood of having MS than an individual having a "C" at that position. The presence of a "T" (the variant nucleotide) at
10 position 226 in both alleles (i.e., homozygous for the *CD24^v* allele) indicates that an individual who has been diagnosed with MS has a greater likelihood of experiencing more rapid progression of MS as compared to individuals who are either homozygous for the wild-type *CD24^a* allele or are heterozygous (*CD24^{a/v}*).

In another embodiment, the invention relates to a method for diagnosing and individual
15 as having or likely to develop MS, or of predicting that an individual who has been diagnosed with MS will experience more rapid progression of the disease, comprising the steps of obtaining a nucleic acid sample from an individual to be assessed, determining the HLA genotype of the individual, and determining the nucleotide present at nucleotide position 226 of the CD24 gene. The presence of the HLA genotype DR2 together with the presence of a "T" (the variant
20 nucleotide) at both alleles of position 226 (i.e., homozygous for the *CD24^v* allele) indicates that the individual has a greater likelihood of having MS than an individual lacking the DR2 genotype and having a "C" at position 226, and that an individual who has been diagnosed with MS has a greater likelihood of experiencing more rapid progression of MS as compared to

individuals who are either homozygous for the wild-type *CD24^w* allele or are heterozygous (*CD24^{w/v}*).

In yet another embodiment, the invention relates to a method for predicting the likelihood that an individual will have or develop MS, or that an individual who has been diagnosed with MS will experience more rapid progression of the disease, by determining the level of cell-surface expression of CD24 in the individual. The method comprises obtaining a cell sample from an individual to be assessed, wherein the sample comprises cells, preferably peripheral blood lymphocytes, most preferably T cells, wherein CD24 is expressed on the cells surfaces thereof. The level of cell-surface expression of CD24 is determined, wherein an increased level of expression as compared with control cells correlates with the presence of a SNP at nucleic acid position 226 in the CD24 gene, and indicates that the individual has an increased likelihood of developing MS. In one embodiment, the level of cell surface expression of CD24 is determined by contacting the cell sample with an excess of fluorochrome-labeled anti-human antibodies specific for CD24 in conjunction with antibodies specific for CD3 (T-cell markers), and determining the level of binding of the antibodies on a per-T cell basis using flow cytometry.

The invention is also drawn to kits for use the methods of the present invention. In one embodiment, the kit comprises a nucleic acid probe, wherein said probe allows the identification of the nucleotide at position 226 of the CD24 gene. The kit can also include control nucleic acid samples. The control nucleic acid samples can include, for example, the homozygous wild-type genotype, homozygous variant genotype and the heterozygous genotype at nucleotide position 226 of the CD24 gene. In one embodiment the kit comprises control nucleic acid samples representing the genotype of at least one of the group consisting of: an individual homozygous

for a "T" at nucleotide position 226 of a CD24 gene, an individual homozygous for a "C" at nucleotide position 226 of a CD24 gene and an individual heterozygous for said position.

In another embodiment, the kit comprises at least one antibody, selected from the group consisting of: an antibody specific for CD24 or fragment thereof and an antibody specific for T
5 cells.

The inventive methods are advantageous in that they provide predictive information regarding the risk that an individual will develop MS and the likelihood that an individual who has been diagnosed with MS will experience rapid progression of the disease. Such predictive information can be used to assist in further evaluation of an individual to determine whether they
10 have or may develop MS. Such predictive information may also be used to develop customized treatment plans for the individual. The design of such customized plans may involve altering the timing and dosage of standard treatment regimens based on whether the individual is heterozygous for the variant allele or homozygous for either the wild-type or variant allele at position 226. By customizing treatment of MS based on a patient's CD24 genetic profile, an
15 improved outcome may be achieved for the patient, along with time and cost savings that are afforded by foregoing unnecessary therapy.

Brief Description of the Drawings

Fig. A shows the polynucleotide sequence for human CD24.

Fig. B shows the polypeptide sequence for human CD24.

Fig. 1. shows the distribution of CD24 genotypes among MS patients and normal population control. a. The reported SNP of CD24 gene and its resulted amino acid replacement. Note that
20 the Alanine (A) to Valine (V) change occurs immediately preceding the site (ω) for the GPI

cleavage. b. Example of genotyping by PCR followed by restriction enzyme digestion. The samples are from normal donors. The genotypes of the individuals are marked in the lanes. c. Distribution of CD24 genotypes among normal population control (unfilled bars), and MS patients (filled bars). The data are based on analysis of 207 normal control and 242 MS patients.

5 The distribution of the genotypes is as follows: normal ($CD24^{a/a}$:109, $CD24^{a/v}$: 85, $CD24^{v/v}$:13) and MS ($CD24^{a/a}$:113, $CD24^{a/v}$: 97, $CD24^{v/v}$ 32). The p values are given in the panel.

Fig. 2. shows MS types of MS patients for whom CD24 genotype analyses were conducted. The diagrams of type I (a) and type II (b) families used for the TDT analysis. The numbers in the parentheses following the genotypes are the ages of the donor when the samples were collected. For patients with genetic data, the EDSS scores were also provided. The nuclear families used for analysis are circled.

10 Fig. 3. shows CD24 genotypes and the time-span of MS patients from the year of first MS symptoms to the year they reached EDSS 6.0. Note that 50% of patients with $CD24^{v/v}$ genotype reached EDSS 6.0 by 5 years as compared to 13 years for the $CD24^{a/a}$ or 16 years for $CD24^{a/v}$ patients. The p values are given in the panel.

15 Fig. 4. shows results of peripheral blood lymphocyte analyses comparing expression levels of various CD24 alleles. Higher expression of CD24 on T cells from patients with $CD24^v$ allele. PBL was isolated from blood of 10 MS patients who belong to either $CD24^{a/a}$ or $CD24^{v/v}$ genotypes with approximate match in age, sex and EDSS (see Table 1 for details). The cells were stained for CD3 and CD24 markers. a. Contour graphs depicting expressing of CD24 and CD3 among the PBL of a representative patient in $CD24^{a/a}$ and $CD24^{v/v}$ groups. b. The mean fluorescence of total PBL or gated $CD3^+$ T cells. Data presented are means and SEM (n=5). c,

as in b, except that the expression of CD24 was compared between $CD24^{n/a}$ and $CD24^{n/v}$ patients (n=6).

Fig. 5 shows results of in vitro experiments comparing expression levels of various CD24 alleles. $CD24^v$ is expressed at higher levels than $CD24^a$ allele in both transient (a) and stable (b)

- 5 CHO cell transfectants. $CD24^v$ and $CD24^a$ were cloned into PCDNA3 vector. a. CHO cells were transfected with varying amounts of CD24 cDNA. At 65 hours after transfection, the transfected CHO cells were stained with saturating amounts of PE-conjugated anti-CD24 mAbs. The y-axis, the CD24 expression, shows the products of % of CD24 expressing cells and mean fluorescence intensity of the positive cells. The means \pm S.D. of triplicate samples are shown.
- 10 The data are representative of 3 independent experiments. b. Comparison of $CD24^v$ and $CD24^a$ expression after removing non-expressing cells by neomycin selection. At 48 hours after transfection, the CHO cells were selected with G418. The short-term drug-resistant culture (consisting of about 500-1000 clones) were pooled and stained with saturating amounts of PE-conjugated anti-CD24 mAbs. Data shown were means \pm S.D. of three independent analyses.
- 15 The background fluorescence of untransfected CHO cells was subtracted. The p values from student t-tests are given in the panels.

Detailed Description of the Invention

Background

- 20 Much of the genetic variation between organisms of the same species is a result of random mutation at specific nucleotide positions which results in the creation of multiple allelic forms of the same gene. As used herein, polymorphism refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population. A polymorphic marker or site is the locus at which divergence occurs. Preferred markers have at least two alleles, each

occurring at frequency of greater than 1%, and more preferably greater than 10% or 20% of a selected population. A polymorphic locus may be as small as one base pair, in which case it is referred to as a single nucleotide polymorphism. These single nucleotide polymorphisms (SNPs, pronounced snips) have the potential to produce profound effects on gene expression and consequently phenotype. For example, a SNP can alter the stability of mRNA by changing binding sites or secondary structure, thus making the mRNA more or less likely to be degraded. A SNP can change promoter binding sites and thereby modify the affinity for a transcription factor. Nonsense SNPs can introduce a premature stop codon that produces a truncated polypeptide, often resulting in loss of function of the gene product. Missense SNPs result in amino acid changes that can result in a functional change in the gene product if the properties of the new amino acid (charge, polarity, etc) are different from the one it replaced.

We have previously reported a critical role for CD24 in the development of EAE (13), the mouse model for MS. To explore the significance of this finding in human MS, we addressed the potential contribution of polymorphisms in MS susceptibility. It has been described that the human CD24 gene has a SNP that encodes a non-conservative replacement of an amino acid (from Alanine in *CD24*^{226a} to Valine in *CD24*^{226v}) immediately preceding the putative cleavage site for the GPI anchor (ω -1 position) (24). Here we show that the *CD24*^{226v/v} genotype is associated with increased risk for developing MS and more rapid progression of MS in patients diagnosed with the disease. As we describe herein, the *CD24*^{226v} is more efficiently expressed on the surface of T lymphocytes, and other cells, in contrast to *CD24*^{226a}. This effect on cell surface expression may influence MS pathogenesis. To our knowledge, this is the first SNP to have a significant impact on MS susceptibility and disease progression. Since MS patients have high frequency of autoreactive T cells, molecules that control events after T cell activation present

unique therapeutic targets. CD24 is one such post-T cell activation target for therapy of human MS. Our data reported here provide three lines of evidence for a significant contribution of the CD24 polymorphism at nucleic acid position 226 to the risk and progression of MS.

First, analysis of the distribution of the CD24 genotypes among more than 200 MS patients and the general population of the central Ohio region indicated that the frequency of the *CD24*^{226w/v} genotype in MS patients is more than twice that of the general population. This result suggests the *CD24*^{226w/v} homozygosity raises the relative risk of MS by more than 2-fold. It would be of great interest to test this correlation in other cohorts.

Second, using the combined TDT and S-TDT tests, we showed that the *CD24*^{226v} allele is preferentially transmitted to the affected individuals in comparison to unaffected individuals. These data confirm that the association at the population level most likely reflects that either CD24 or a gene linked to CD24 contributes to MS susceptibility in human.

Third, in addition to an increased risk of MS, the MS patients with *CD24*^{226w/v} genotype also have a more rapid progression, as judged by the time lapse between the first MS symptom and the time when a walking aid needs to be prescribed. We have chosen EDSS 6.0 as the pre-determined endpoint in experimental designs as this is a readily identifiable milestone in MS progression. We found that among the patients that have reached EDSS 6.0, 50% of the *CD24*^{226w/v} patients reached that milestone in 5 years, while *CD24*^{226a/a} and *CD24*^{226a/v} patients did so in 13 and 16 years, respectively. More rapid progression in the *CD24*^{226w/v} patients suggests that more aggressive treatment may be warranted in this group of patients.

An important issue is how the CD24 SNP at nucleic acid position 226 affects the risk and progression of MS. The CD24 gene product is a GPI anchored molecule with approximately 32 amino acids in the mature protein (after post-translational cleavage of portions). The SNP at

nucleic acid position 226 in CD24 results in a non-conservative replacement from Alanine to Valine at the site immediately preceding the putative cleavage site for GPI anchor (called the ω -1). Although strict conservation at this site is not necessary for the cleavage and anchor attachment, there appears to be a general requirement for the total sites of the 4 amino acids at positions $\omega+1$, $+2$ $\omega-1$, and -2 (34). Since the Alanine and Valine have a substantial difference in size, it is plausible that these two alleles may be expressed at slightly different efficiency. Our comparison revealed that the *CD24*^{226v} allele is expressed at 30-40% higher levels than the *CD24*^{226a} allele.

Indeed, the T cells in the peripheral blood of the *CD24*^{226n/v} patients expressed significantly higher levels of CD24 than those in the blood of the *CD24*^{226a/a} patients. Although resting T cells expressed very little CD24 in the mouse, its expression is rapidly induced after activation (14, 23). Since our previous work established that CD24 gene must be functional in T cells for the T cells to be pathogenic (13), the induction of CD24 in T cells may be an important checkpoint for the pathogenesis of MS. For this reason, more efficient expression of *CD24*^{226v} alleles on T cells may provide a plausible explanation for the increased risk and progression of MS in the *CD24*^{226v/v} patients. The more efficient expression of CD24, however, is not necessarily limited to T cells, as the *CD24*^{226v} cDNA is more efficiently expressed even in CHO cells. Thus, the statistically insignificant difference among total PBL is most likely secondary to the vast variation in the proportion of leukocyte subsets with varying levels of CD24 (data not shown).

CD24^{226vv} Genotype and Increased MS Risk in Population Study

We obtained 207 unused blood samples from the American Red Cross in Columbus and 243 samples of MS patients for the distribution of CD24 genotypes. The demography of the normal control population was not collected among the American Red Cross samples, but is assumed to reflect the general demography of the Central Ohio population. Moreover, the distribution of the CD24 genotype among our control population is similar to what was reported in a small population analysis in Europe (24). Among the 242 MS samples, 233 were from Caucasian, 7 were from African-American, 1 from Hispanics and one from Asian. The race distribution of the samples reflected both the demography of the Central Ohio population and the higher incidence of MS among the Caucasian, but not selective recruitment.

As shown in Fig. 1a, the CD24 genotype can be distinguished by digesting the PCR products of CD24 with *Bst*XI. The CD24^{226a/a} products were completely resistant to the digestion, while the CD24^{226v/v} products cleaved into two fragments of 317 and 136 bp. Partial digestion of 50% or less indicated CD24^{226a/v} genotype. We therefore used this method to genotype the DNA isolated from leukocytes of normal population control and MS patients. The distribution of the genotypes among normal (CD24^{226a/a}:109, CD24^{226a/v}: 85, CD24^{226v/v}:13) and MS (CD24^{226a/a}:113, CD24^{226a/v}: 97, CD24^{226v/v}: 32) were compared by the Chi-square test. It was revealed that the distribution of CD24 genotypes among the MS patients appeared to differ significantly from that of the normal controls (p=0.048). The difference is significant among the CD24^{226v/v} genotype (6.3% in control vs 13.2% in MS, p=0.023), even after Bonferroni correction for multiple testing. The increased risk among the CD24^{226v/v} individuals of about 2-fold suggests that the CD24 gene may be a modifier for MS susceptibility. Although some of the patients are related, they are treated as independent samples in the tests.

Association of the $CD24^{226v}$ Allele with MS in Family Study

Eleven trios (type I families) and 18 sibships (type II families) from the multiplex families were extracted. See Fig. 2a and Fig. 2b for an example of each of these two types of families. Three of the type I families and one of the type II families are from the same extended pedigree. However, the three type I families are only distantly related that they can be treated as independent for our purpose, and are included in our TDT analysis (yielding a total of 28 informative nuclear families). Among the 11 trios, there were 15 heterozygous parents with genotypes $CD24^{226a/v}$, of which 13 transmitted the v allele to their affected children. The contribution to the overall test statistic was thus $X_{TDT} = 13$, much larger than the expected value of 7.5. Among the 17 sibships, the total number of v alleles among the affected siblings is $X_{TDT} = 20$, still larger than the expected value of 18.57, although the discrepancy between the observed and the expected was not as striking as in the trios. Our Monte Carlo procedure with 1,000,000 simulated null data sets yielded a significant result for the combined test statistic, $X_{obs} = X_{TDT} + X_{STDT} = 33$ ($P=0.017$). A pedigree TDT test that takes family dependency into account (31) yielded similarly significant result.

Taken together, both the TDT test for the family data and the Chi-square tests for the population data suggest that $CD24^v$ allele is a significant risk factor for the incidence of MS.

$CD24$ Genotype Affects Progression of MS

The MS disease severity is usually measured according to the expanded disability status scale (EDSS) score. MS patients that have lost the ability to walk without aid would have reached EDSS 6.0. For the majority of the patients, their EDSS 6.0 was based on follow-up at our center. A few of the cases were based on interview. Since this is one of the most traumatic

events in the patient's life, most MS patients can recall accurately the time when their disease reached EDSS 6.0. We have chosen all patients that have EDSS of 6.0 or higher, which resulted in 57, 40, and 15 patients with genotype *a/a*, *a/v*, and *v/v*, respectively. We then tested whether the CD24 genotype affected the time span it took the patients to reach EDSS 6.0 from the day of the first symptom of MS. As shown in Fig. 3, 50% of the *CD24*^{226v/v} patients reached EDSS 6.0 in 5 years after the first symptom, whereas those with *CD24*^{226a/a} and *CD24*^{226a/v} genotypes reached EDSS 6.0 in 13 and 16 years, respectively.

Furthermore, comparison of the three estimated survival curves in Fig. 3 reveals that the CD24 genotypes have significant impact on the progression ($p=0.0008$). Pair-wise comparisons further show that *CD24*^{226v/v} patients progressed more rapidly towards EDSS 6.0 than both *CD24*^{226a/v} patients ($p=0.00037$) and *CD24*^{226a/a} patients ($p=0.0016$), even after Bonferroni correction. There is no significant difference between *CD24*^{226a/a} and *CD24*^{226a/v} patients ($p=0.30$).

Determination of Cell Surface Expression of *CD24*^{226v}

The CD24 is a GPI anchored molecule, and therefore needs to be cleaved of C-terminal sequence prior to GPI attachment (32, 33). This cleavage requires specific sequence at and near the cleavage site (ω), $\omega+1$ and $\omega+2$ sites (32, 33). Moreover, systematic analysis of all GPI anchored proteins with known cleavage sites suggests that although the amino acid at the $\omega-1$ and $\omega-2$ positions may have a quantitative effect on the cleavage efficiency, as the optimal cleavage requires that the side chains in the 4 positions have a combined volume of 430\AA^3 (34). As shown in Fig. 1a, *CD24*^{226v} and *CD24*^{226a} have a non-conservative replacement of A by V at the $\omega-1$ site. Since all 4 amino acids in *CD24*^{226a} have the small side chains (A and G),

replacement of A with V at ω -1 may increase the efficiency of cleavage. As a result, the $CD24^{226v}$ protein may be expressed at a higher level than the $CD24^{226a}$ proteins. To test this notion, we analyzed CD24 expression on the peripheral blood leukocytes of age, sex and disease-status matched $CD24^{226a/a}$ and $CD24^{226v/v}$ MS patients (Table 1, experiment 1) by two-color flow

5 cytometry. The profiles of a representative sample in each group were presented in Figure 4a, while the mean fluorescence intensities of total PBL and $CD3^+$ T cells among the PBL were summarized in Fig. 4b. As shown in Fig. 4a, CD24 is expressed on both T cells and non-T cells, regardless of the genotypes of the MS patients. However, the % of positive cells and intensity of expression were higher among the PBL of $CD24^{226v/v}$ patients. Interestingly, $CD3^+$ T cells from

10 the $CD24^{226a/a}$ patients expressed 6-fold less cell-surface CD24 than those from the $CD24^{226v/v}$ patients. While the same trend was found for total PBL, this was not statistically significant. In a separate experiment, we also compared 6 $CD24^{226a/a}$ and 6 $CD24^{226a/v}$ patients for the CD24 expression. Although the MS type was not well matched in this experiment, the MS type did not appear to influence the CD24 expression (Table 1). As shown in Table 1 (Exp. 2) and Fig. 4c,

15 although the $CD24^{226a/v}$ T cells expressed higher CD24 than the $CD24^{226a/a}$ T cells, the increase is less than 2-fold. The small increase may explain why the $CD24^{226a/v}$ genotype had no measurable effect on the risk and progression of MS.

To directly address whether CD24 SNP caused variation in CD24 expression, we cloned both $CD24^{226v}$ and $CD24^{226a}$ cDNA and transfected the CHO cells with different concentrations

20 of plasmids. Three days after the transfection, the cell surface expression of the CD24 gene was analyzed by flow cytometry. As shown in Fig. 5a, across a wide range of doses, the $CD24^{226v}$ cDNA resulted in 30-40% more cell surface expression of CD24 when compared with the $CD24^{226a}$ cDNA. To avoid variation in transfection, we also used the neomycin selection to

remove untransfected cells, and compared the pooled drug resistant clones for their CD24 expression. Again, *CD24^{226v}* cDNA transfectants expressed significantly higher cell surface CD24 (Fig. 5b).

Isolation and SNP Genotype Analysis of Nucleic Acids

5 The genetic material to be assessed can be obtained from any nucleated cell from the individual being tested. For assay of genomic DNA, virtually any biological sample (other than pure red blood cells) is suitable. For example, convenient tissue samples include whole blood, semen, saliva, tears, urine, fecal material, sweat, skin and hair. For assay of cDNA or mRNA, the tissue sample must be obtained from cells in which the target nucleic acid is expressed,
10 preferably from T lymphocytes.

The nucleotide which occupies the polymorphic site of interest (e.g., nucleotide position 226 in CD24) can be identified by a variety methods, such as Southern analysis of genomic DNA; direct mutation analysis by restriction enzyme digestion; Northern analysis of RNA; denaturing high pressure liquid chromatography (DHPLC); gene isolation and sequencing;
15 hybridization of an allele-specific oligonucleotide with amplified gene products; single base extension (SBE); or analysis of the cell-surface expression of the CD24 protein. A sampling of suitable procedures are discussed below:

Allele-Specific Probes The design and use of allele-specific probes for analyzing polymorphisms is described by e.g., Saiki et al., Nature 324, 163-166 (1986); Dattagupta, EP
20 235,726, Saiki, WO 89/11548. Allele-specific probes can be designed that hybridize to a segment of target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms in the respective

segments from the two individuals. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Hybridizations are usually performed under stringent conditions, for example, at a salt concentration of no more than 1 M and a temperature of at least 25°C. For example, conditions of 5.times.SSPE (750 mM NaCl, 50 mM NaPhosphate, 5 mM EDTA, pH 7.4) and a temperature of 25-30°C, or equivalent conditions, are suitable for allele-specific probe hybridizations. Equivalent conditions can be determined by varying one or more of the parameters given as an example, as known in the art, while maintaining a similar degree of identity or similarity between the target nucleotide sequence and the primer or probe used.

Some probes are designed to hybridize to a segment of target DNA such that the polymorphic site aligns with a central position (e.g., in a 15-mer at the 7 position; in a 16-mer, at either the 8 or 9 position) of the probe. This design of probe achieves good discrimination in hybridization between different allelic forms.

Allele-specific probes are often used in pairs, one member of a pair showing a perfect match to a reference form of a target sequence and the other member showing a perfect match to a variant form. Several pairs of probes can then be immobilized on the same support for simultaneous analysis of multiple polymorphisms within the same target sequence.

Tiling Arrays The polymorphisms can also be identified by hybridization to nucleic acid arrays, some examples of which are described in WO 95/11995. WO 95/11995 also describes subarrays that are optimized for detection of a variant form of a precharacterized polymorphism. Such a subarray contains probes designed to be complementary to a second reference sequence, which is an allelic variant of the first reference sequence. The second group of probes is designed by the

same principles, except that the probes exhibit complementarity to the second reference sequence. The inclusion of a second group (or further groups) can be particularly useful for analyzing short subsequences of the primary reference sequence in which multiple mutations are expected to occur within a short distance commensurate with the length of the probes (e.g., two
5 or more mutations within 9 to 21 bases).

Allele-Specific Primers An allele-specific primer hybridizes to a site on target DNA overlapping a polymorphism and only primes amplification of an allelic form to which the primer exhibits perfect complementarity. See Gibbs, Nucleic Acid Res. 17, 2427-2448 (1989). This primer is used in conjunction with a second primer which hybridizes at a distal site. Amplification
10 proceeds from the two primers, resulting in a detectable product which indicates the particular allelic form is present. A control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site. The single-base mismatch prevents amplification and no detectable product is formed. The method works best when the mismatch is included in the 3'-
15 most position of the oligonucleotide aligned with the polymorphism because this position is most destabilizing to elongation from the primer (see, e.g., WO 93/22456).

Primers are selected within the conserved regions shown in the attached alignment 1 to amplify a fragment with proper size for optimal detection. One primer is located at each end of the sequence to be amplified. Such primers will normally be between 10 to 30 nucleotides in
20 length and have a preferred length from between 18 to 22 nucleotides. The smallest sequence that can be amplified is approximately 50 nucleotides in length (e.g., a forward and reverse primer, both of 20 nucleotides in length, whose location in the sequences is separated by at least 10 nucleotides). Much longer sequences can be amplified. Preferably, the length of sequence

amplified is between 75 and 250 nucleotides in length, and between 75 and 150 for Taqman assay.

One primer is called the “forward primer” and is located at the left end of the region to be amplified. The forward primer is identical in sequence to a region in the top strand of the DNA (when a double-stranded DNA is pictured using the convention where the top strand is shown with polarity in the 5’ to 3’ direction). The sequence of the forward primer is such that it hybridizes to the strand of the DNA which is complementary to the top strand of DNA.

The other primer is called the “reverse primer” and is located at the right end of the region to be amplified. The sequence of the reverse primer is such that it is complementary in sequence to, i.e., it is the reverse complement of a sequence in, a region in the top strand of the DNA. The reverse primer hybridizes to the top strand of the DNA.

PCR primers should also be chosen subject to a number of other conditions. PCR primers should be long enough (preferably 10 to 30 nucleotides in length) to minimize hybridization to greater than one region in the template. Primers with long runs of a single base should be avoided, if possible. Primers should preferably have a percent G+C content of between 40 and 60%. If possible, the percent G+C content of the 3’ end of the primer should be higher than the percent G+C content of the 5’ end of the primer. Primers should not contain sequences that can hybridize to another sequence within the primer (i.e., palindromes). Two primers used in the same PCR reaction should not be able to hybridize to one another. Although PCR primers are preferably chosen subject to the recommendations above, it is not necessary that the primers conform to these conditions. Other primers may work, but have a lower chance of yielding good results.

PCR primers that can be used to amplify DNA within a given sequence can be chosen using one of a number of computer programs that are available. Such programs choose primers that are optimum for amplification of a given sequence (i.e., such programs choose primers subject to the conditions stated above, plus other conditions that may maximize the functionality of PCR primers). One computer program is the Genetics Computer Group (GCG recently became Accelrys) analysis package which has a routine for selection of PCR primers. There are also several web sites that can be used to select optimal PCR primers to amplify an input sequence. One such web site is <http://alces.med.umn.edu/rawprimer.html>. Another such web site is http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi.

- 10 Direct-Sequencing The direct analysis of the sequence of polymorphisms of the present invention can be accomplished using either the dideoxy chain termination method or the Maxam-Gilbert method (see Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd Ed., CSHP, New York 1989); Zyskind et al., Recombinant DNA Laboratory Manual, (Acad. Press, 1988)).

- 15 Denaturing Gradient Gel Electrophoresis Amplification products generated using the polymerase chain reaction can be analyzed by the use of denaturing gradient gel electrophoresis. Different alleles can be identified based on the different sequence-dependent melting properties and electrophoretic migration of DNA in solution. Erlich, ed., PCR Technology, Principles and Applications for DNA Amplification, (W. H. Freeman and Co, New York, 1992), Chapter 7.

- 20 Examples of other techniques for detecting alleles include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation or nucleotide difference (e.g., in allelic variants) is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Said et al.

(1986) Nature 324:163); Saiki et al (1989) Proc. Natl Acad. Sci USA 86:6230). Such allele specific oligonucleotide hybridization techniques may be used to test one mutation or polymorphic region per reaction when oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations or polymorphic regions when the oligonucleotides are
5 attached to the hybridizing membrane and hybridized with labelled target DNA.

Alternatively, allele specific amplification technology which depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation or polymorphic region of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs et al
10 (1989) Nucleic Acids Res. 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) Tibtech 11:238. In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini et al (1992) Mol. Cell Probes 6:1). It is anticipated that in certain embodiments amplification may also be performed using Taq
15 ligase for amplification (Barany (1991) Proc. Natl. Acad. Sci USA 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

In another embodiment, identification of the allelic variant is carried out using an
20 oligonucleotide ligation assay (OLA), as described, e.g., in U.S. Pat. No. 4,998,617 and in Landegren, U. et al. ((1988) Science 241:1077-1080). The OLA protocol uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target. One of the oligonucleotides is linked to a separation marker, e.g.,

biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate. Ligation then permits the labeled oligonucleotide to be recovered using avidin, or another biotin ligand. Nickerson, D. A. et al. have described a nucleic acid detection assay that combines attributes of PCR and OLA (Nickerson, D. A. et al. (1990) Proc. Natl. Acad. Sci. USA 87:8923-27). In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA.

Several techniques based on this OLA method have been developed and can be used to detect CD24 alleles. For example, U.S. Pat. No. 5,593,826 discloses an OLA using an oligonucleotide having 3'-amino group and a 5'-phosphorylated oligonucleotide to form a conjugate having a phosphoramidate linkage. In another variation of OLA described in Tobe et al. ((1996) Nucleic Acids Res 24: 3728), OLA combined with PCR permits typing of two alleles in a single microtiter well. By marking each of the allele-specific primers with a unique hapten, i.e. digoxigenin and fluorescein, each OLA reaction can be detected by using hapten specific antibodies that are labeled with different enzyme reporters, alkaline phosphatase or horseradish peroxidase. This system permits the detection of the two alleles using a high throughput format that leads to the production of two different colors.

Many of the methods described herein require amplification of DNA from target samples. This can be accomplished by e.g., PCR. See generally PCR Technology: Principles and Applications for DNA Amplification (ed. H. A. Erlich, Freeman Press, New York, N.Y., 1992); PCR Protocols: A Guide to Methods and Applications (eds. Innis, et al., Academic Press, San Diego, Calif., 1990); Mattila et al., Nucleic Acids Res. 19, 4967 (1991); Eckert et al., PCR

Methods and Applications 1, 17 (1991); PCR (eds. McPherson et al., IRL Press, Oxford); and U.S. Pat. No. 4,683,202.

Other suitable amplification methods include the ligase chain reaction (LCR) (see Wu and Wallace, Genomics 4, 560 (1989), Landegren et al., Science 241, 1077 (1988), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86, 1173 (1989)), and self-sustained sequence replication (Guatelli et al., Proc. Nat. Acad. Sci. USA, 87, 1874 (1990)) and nucleic acid based sequence amplification (NASBA). The latter two amplification methods involve isothermal reactions based on isothermal transcription, which produce both single stranded RNA (ssRNA) and double stranded DNA (dsDNA) as the amplification products in a ratio of about 30 or 100 to 1, respectively.

Correlation of MS Phenotype with SNP Analyses

Correlation between a particular phenotype, e.g., MS symptoms, and the presence or absence of a particular CD24 SNP allele is performed for a population of individuals who have been tested for the presence or absence of the phenotype. Correlation can be performed by standard statistical methods such as a Chi-squared test and statistically significant correlations between polymorphic form(s) and phenotypic characteristics are noted. For example, as described herein, it has been found that the presence of the CD24 variant allele at nucleic acid position 226, with a replacement of the C at polymorphic site 226 with a T, correlates positively with MS with a p value of $p=0.023$ by Chi-squared test.

This correlation can be exploited in several ways. In the case of a strong correlation between a particular polymorphic form, detection of the polymorphic form in an individual may justify immediate administration of treatment, or at least the institution of regular monitoring of the individual. Detection of a polymorphic form correlated with a disorder in a couple

contemplating a family may also be valuable to the couple in their reproductive decisions. For example, the female partner might elect to undergo in vitro fertilization to avoid the possibility of transmitting such a polymorphism from her husband to her offspring. In the case of a weaker, but still statistically significant correlation between a polymorphic form and a particular disorder, immediate therapeutic intervention or monitoring may not be justified. Nevertheless, the individual can be motivated to begin simple life-style changes (e.g., diet modification, therapy or counseling) that can be accomplished at little cost to the individual but confer potential benefits in reducing the risk of conditions to which the individual may have increased susceptibility by virtue of the particular allele. Furthermore, identification of a polymorphic form correlated with enhanced receptiveness to one of several treatment regimes for a disorder indicates that this treatment regimen should be followed for the individual in question.

Furthermore, it may be possible to identify a physical linkage between a genetic locus associated with a trait of interest (e.g., MS) and polymorphic markers that are or are not associated with the trait, but are in physical proximity with the genetic locus responsible for the trait and co-segregate with it. Such analysis is useful for mapping a genetic locus associated with a phenotypic trait to a chromosomal position, and thereby cloning gene(s) responsible for the trait. See Lander et al., *Proc. Natl. Acad. Sci. (USA)* 83, 7353-7357 (1986); Lander et al., *Proc. Natl. Acad. Sci. (USA)* 84, 2363-2367 (1987); Donis-Keller et al., *Cell* 51, 319-337 (1987); Lander et al., *Genetics* 121, 185-199 (1989)). Genes localized by linkage can be cloned by a process known as directional cloning. See Wainwright, *Med. J. Australia* 159, 170-174 (1993); Collins, *Nature Genetics* 1, 3-6 (1992).

Linkage studies are typically performed on members of a family. Available members of the family are characterized for the presence or absence of a phenotypic trait and for a set of

polymorphic markers. The distribution of polymorphic markers in an informative meiosis is then analyzed to determine which polymorphic markers co-segregate with a phenotypic trait. See, e.g., Kerem et al., *Science* 245, 1073-1080 (1989); Monaco et al., *Nature* 316, 842 (1985); Yamoka et al., *Neurology* 40, 222-226 (1990); Rossiter et al., *FASEB Journal* 5, 21-27 (1991).

5 Linkage is analyzed by calculation of LOD (log of the odds) values. A LOD value is the relative likelihood of obtaining observed segregation data for a marker and a genetic locus when the two are located at a recombination fraction θ , versus the situation in which the two are not linked, and thus segregating independently (Thompson & Thompson, *Genetics in Medicine* (5th ed, W. B. Saunders Company, Philadelphia, 1991); Strachan, "Mapping the human genome" in *The Human Genome* (BIOS Scientific Publishers Ltd, Oxford), Chapter 4). A series of likelihood ratios are calculated at various recombination fractions (θ), ranging from $\theta=0.0$ (coincident loci) to $\theta=0.50$ (unlinked). Thus, the likelihood at a given value of θ is: probability of data if loci linked at θ to probability of data if loci unlinked. The computed likelihoods are usually expressed as the \log_{10} of this ratio (i.e., a LOD score).
 10 For example, a LOD score of 3 indicates 1000:1 odds against an apparent observed linkage being a coincidence. The use of logarithms allows data collected from different families to be combined by simple addition. Computer programs are available for the calculation of LOD scores for differing values of θ . (e.g., LIPED, MLINK (Lathrop, *Proc. Nat. Acad. Sci. (USA)* 81, 3443-3446 (1984)). For any particular LOD score, a recombination fraction may be
 15 determined from mathematical tables. See Smith et al., *Mathematical tables for research workers in human genetics* (Churchill, London, 1961); Smith, *Ann. Hum. Genet.* 32, 127-150 (1968). The value of θ at which the LOD score is the highest is considered to be the best estimate of the recombination fraction.

Positive LOD score values suggest that the two loci are linked, whereas negative values suggest that linkage is less likely (at that value of θ) than the possibility that the two loci are unlinked. By convention, a combined LOD score of +3 or greater (equivalent to greater than 1000:1 odds in favor of linkage) is considered definitive evidence that two loci are linked.

5 Similarly, by convention, a negative LOD score of -2 or less is taken as definitive evidence against linkage of the two loci being compared. Negative linkage data are useful in excluding a chromosome or a segment thereof from consideration. The search focuses on the remaining non-excluded chromosomal locations.

10 EXAMPLES

Example 1: PCR Amplification and RFLP analysis of CD24 Gene

Collection of Samples

All sample collection and experimentation have been approved by the Institutional Review Board (IRB), and informed consents from all participants were obtained prior to sample
 15 collection. Patients with definite MS, as diagnosed by KR at the Ohio State University MS Center according to the McDonald criteria (25), were offered the opportunity to participate. Consenting family members with or without MS provided blood samples as well. When family members were in other sites, samples were obtained by a local physician or nurse and transported or mailed to our center. Ascertainment of presence or absence of MS amongst the relatives was
 20 by history only, and relatives who provided blood samples were not subject to neurological evaluation or Magnetic Resonance Imaging (MRI) at our center. Of the 498 samples that yielded

valid genotyping information, 242 were from MS patients and 256 were from the non-MS relatives. Only multiplex families were used for association analysis.

The clinical diagnosis of MS type and the Expanded Disability Status Scale (EDSS) (26) were determined. The time of first onset and the time when the patients were first prescribed a walking aid (EDSS 6.0) was determined retrospectively by analysis of case record.

Leftover blood samples from American Red Cross at Columbus were used as population control. A total of 207 samples were selected on basis of availability only over a one-year period. It is therefore expected that the genetic distribution resembles that of the Central Ohio population from which most of the patients and their family members were recruited.

10 Analysis

The reported SNP for CD24 is a replacement of C at nucleotide (nt) 226 by T (C>T) in the coding region of exon 2 (Gene bank accession: NM_013230), which results in a substitution of Ala at amino acid 57 by Val near the GPI-anchorage site of the mature protein. The genomic DNA was isolated from approximately 5×10^6 human peripheral blood leukocytes (PBL) using QIAamp DNA blood mini-kit (Qiagen Inc, Valencia, CA). DNA fragments bearing this SNP site were amplified by PCR using a forward (ttg ttg cca ctt ggc att ttt gag gc) and a reverse primer (gga ttg ggt tta gaa gat ggg gaa a). The PCR conditions were: 94°C for 1 min, 50°C for 1 min and 72°C for 1 min, for 35 cycles. The predicted CD24 PCR fragment is 453 bp long. The C>T change yielded a *Bst*XI restriction enzyme site at nt 215, which allowed us to differentiate these two different CD24 alleles by RFLP analysis. Briefly, an aliquot of CD24 PCR products were digested with *Bst*XI for 16 hours at 50°C. The digested products were then separated in a 2.5 % agarose gel. The predicted digestion pattern is as follows: PCR products of T226 allele will be cut into two small fragments (317 bp and 136 bp), while those of the C226 will be

completely resistant. A combination of the two types of the products at close to 50% levels will indicate the heterozygosity of the subject.

Example 2: Molecular cloning and expression of *CD24^{v/v}* and *CD24^{a/a}* cDNA

The CD24 cDNA was amplified from PBL or *CD24^{v/v}* and *CD24^{a/a}* individuals by RT-PCR. The primers used were: Forward (CD24F.H3): ggccaagcttatgggcagagcaatggtg; and reverse (CD24R.XhoI): atccctcgagtaagagtagagatgcag. The PCR products (256 bp) were digested with *HindIII/XhoI* and then cloned into pCDNA3 expression vector at *HindIII/XhoI* site, thus generating plasmid pCDNA3-CD24A and pCDNA3-CD24V. The sequence of CD24 cDNA inserts was confirmed by DNA sequencing. To test the expression efficiency of the two CD24 alleles, we transfected varying concentrations of the plasmids into the CHO cells using the fuge 6, as described (27). Three days after transfection, the cell surface expression of the CD24 was determined by flow cytometry, using saturating amounts of anti-CD24 antibodies.

Example 3: Evaluation of *CD24^a* and *CD24^v* expression using Flow Cytometry

Expression of human and mouse CD24 was determined by flow cytometry using fluorochrome-labeled anti-human (B-D Pharmingen, San Diego, CA). PBL were isolated from fresh blood samples and stained with saturating amounts of anti-CD24 antibodies in conjunction with anti-CD3 antibodies to mark the T cells among the PBL.

Example 4: Statistical analysis

Case-control population study

MS patients and normal controls were examined for significant differences in their genotype distributions in the CD24 SNP at the population level. Most of the cases and the control subjects were from Central Ohio, reflecting, at least to some extent, a similarity in the

disease and control populations. Pearson's Chi-square test (28) was used to perform the homogeneity test between the two distributions of the genotypes. In addition, we performed further tests to compare the frequencies of $CD24^{vv}$ genotype between the cases and controls, again using the Chi-square tests, but with Yates' correction. Since the number of individuals
 5 falling into each of the three genotypes in both the cases and controls is fairly large, the Chi-square tests should yield valid estimates of the p-values.

Association test for transmission disequilibrium of the V allele.

Since results from population studies can be affected by population admixture and stratification, we also carried out transmission disequilibrium test (TDT) using family data.
 10 Families with at least two MS patients (multiplex families) are ascertained for our genetic analysis to determine whether, in families that exhibit evidence of familial aggregation, the v allele in the CD24 SNP is transmitted preferentially to MS patients.

Two types of informative nuclear families were extracted from the multiplex families and included in our analysis. The type I families (trios) are those in which there is one MS patient
 15 and both parental genotypes are available with at least one being heterozygous. The type II families (sibships) are those in which both affected and unaffected siblings are available with at least two different genotypes in the sibship. For a family that can be of either type I or type II, it is classified to be a type I family following the recommendation of Spielman and Ewens (29).

A combined TDT (for type I families) and STDT (for type II families) test, as suggested
 20 by Spielman and Ewens (29), but with a Monte Carlo procedure for estimating the p-value, is employed. Specifically, let X_{TDT} denote the total number of V alleles transmitted to the MS patients from heterozygous parents in the type I families. Let X_{STDT} denote the total number of V alleles among the affected siblings in the type II families. Then $X_{obs} = X_{TDT} + X_{STDT}$ is the

observed test statistic for all informative families combined. Although one could estimate the p-value using normal asymptotic as suggested in Spielman and Ewens (29), we opted for the Monte Carlo procedure described in the following to avoid the need to rely on an asymptotic distribution with a moderate sample size.

5 To estimate the p-value of the test, 1,000,000 replicated datasets, under the null hypothesis that the CD24 SNP is unlinked to an MS locus, are generated as follows. For each type I family, we randomly select one of the two alleles in each parent to make up the new genotype of the patient, while the parental genotypes are unchanged. For each type II family, we follow the scheme of Spielman and Ewens (29) by simply permuting the affection status of the
10 individuals in the sibship. For each simulated replicate, a test statistic X is computed. The p-value is taken to be the proportion of the X 's that are equal to, or greater than, the observed statistic, X_{obs} , in the actual data. This Monte Carlo estimate of the p-value should be very close to the true p-value given the large number of replicates performed.

Comparison of survival curves.

15 Patients with MS severity reaching EDSS 6.0 or higher are classified into three groups according to their CD24 genotypes. To assess whether MS progression is different among patients with different genotypes, we first estimated the survival curve, using the Kaplan-Meier method, for each of the three groups, two of which having right censored data. Then the estimated Kaplan-Meier survival curves are compared using the log-rank test (30). Here,
20 survival is taken to mean that a patient has not reached EDSS 6.0 yet, and the time span is measured by the number of years lapsed since the first symptom.

References

1. Noseworthy, J. H. (1999) *Nature* 399, A40-7.
2. Carton, H., Vlietinck, R., Debruyne, J., De Keyser, J., D'Hooghe, M. B., Loos, R., Medaer, R., Truyen, L., Yee, I. M. & Sadovnick, A. D. (1997) *J Neurol Neurosurg Psychiatry* 62, 329-33.
3. Ebers, G. C., Bulman, D. E., Sadovnick, A. D., Paty, D. W., Warren, S., Hader, W., Murray, T. J., Seland, T. P., Duquette, P., Grey, T. & et al. (1986) *N Engl J Med* 315, 1638-42.
4. Kellar-Wood, H. F., Wood, N. W., Holmans, P., Clayton, D., Robertson, N. & Compston, D. A. (1995) *J Neuroimmunol* 58, 183-90.
5. Miller, D. H., Hornabrook, R. W., Dagger, J. & Fong, R. (1989) *J Neurol Neurosurg Psychiatry* 52, 575-7.
6. Morling, N., Sandberg-Wollheim, M., Fugger, L., Georgsen, J., Hylding-Nielsen, J. J., Madsen, H. O., Rieneck, K., Ryder, L. & Svejgaard, A. (1992) *Immunogenetics* 35, 391-4.
7. Olerup, O. & Hillert, J. (1991) *Tissue Antigens* 38, 1-15.
8. Haines, J. L., Ter-Minassian, M., Bazyk, A., Gusella, J. F., Kim, D. J., Terwedow, H., Pericak-Vance, M. A., Rimmmler, J. B., Haynes, C. S., Roses, A. D., Lee, A., Shaner, B., Menold, M., Seboun, E., Fitoussi, R. P., Gartioux, C., Reyes, C., Ribierre, F., Gyapay, G., Weissenbach, J., Hauser, S. L., Goodkin, D. E., Lincoln, R., Usuku, K., Oksenberg, J. R. & et al. (1996) *Nat Genet* 13, 469-71.
9. Sawcer, S., Jones, H. B., Feakes, R., Gray, J., Smaldon, N., Chataway, J., Robertson, N., Clayton, D., Goodfellow, P. N. & Compston, A. (1996) *Nat Genet* 13, 464-8.
10. Ebers, G. C., Kukay, K., Bulman, D. E., Sadovnick, A. D., Rice, G., Anderson, C., Armstrong, H., Cousin, K., Bell, R. B., Hader, W., Paty, D. W., Hashimoto, S., Oger, J., Duquette, P., Warren, S., Gray, T., O'Connor, P., Nath, A., Auty, A., Metz, L., Francis, G., Paulseth, J. E., Murray, T. J., Pryse-Phillips, W., Risch, N. & et al. (1996) *Nat Genet* 13, 472-6.
11. Schmidt, S., Barcellos, L. F., DeSombre, K., Rimmmler, J. B., Lincoln, R. R., Bucher, P., Saunders, A. M., Lai, E., Martin, E. R., Vance, J. M., Oksenberg, J. R., Hauser, S. L., Pericak-Vance, M. A. & Haines, J. L. (2002) *Am J Hum Genet* 70, 708-17.
12. Kuokkanen, S., Sundvall, M., Terwilliger, J. D., Tienari, P. J., Wikstrom, J., Holmdahl, R., Pettersson, U. & Peltonen, L. (1996) *Nat Genet* 13, 477-80.
13. Bai, X. F., Liu, J. Q., Liu, X., Guo, Y., Cox, K., Wen, J., Zheng, P. & Liu, Y. (2000) *J Clin Invest* 105, 1227-32.
14. Hubbe, M. & Altevogt, P. (1994) *Eur J Immunol* 24, 731-7.
15. Zhou, Q., Wu, Y., Nielsen, P. J. & Liu, Y. (1997) *Eur J Immunol* 27, 2524-8.
16. Liu, Y., Jones, B., Aruffo, A., Sullivan, K. M., Linsley, P. S. & Janeway, C. A., Jr. (1992) *J Exp Med* 175, 437-45.

17. De Bruijn, M. L., Peterson, P. A. & Jackson, M. R. (1996) *J Immunol* 156, 2686-92.
18. Enk, A. H. & Katz, S. I. (1994) *J Immunol* 152, 3264-70.
19. Liu, Y., Jones, B., Brady, W., Janeway, C. A., Jr., Linsley, P. S. & Linley, P. S. (1992) *Eur J Immunol* 22, 2855-9.
- 5 20. Liu, Y., Wenger, R. H., Zhao, M. & Nielsen, P. J. (1997) *J Exp Med* 185, 251-62.
21. Wu, Y., Zhou, Q., Zheng, P. & Liu, Y. (1998) *J Exp Med* 187, 1151-6.
22. Hahne, M., Wenger, R. H., Vestweber, D. & Nielsen, P. J. (1994) *J Exp Med* 179, 1391-5.
23. Baron, J. L., Madri, J. A., Ruddie, N. H., Hashim, G. & Janeway, C. A., Jr. (1993) *J Exp Med* 177, 57-68.
- 10 24. Zarn, J. A., Jackson, D. G., Bell, M. V., Jones, T., Weber, E., Sheer, D., Waibel, R. & Stahel, R. A. (1995) *Cytogenet Cell Genet* 70, 119-25.
25. McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H. P., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., Sandberg-Wollheim, M., Sibley, W., Thompson, A., van den Noort, S., Weinshenker, B. Y. & Wolinsky, J. S. (2001) *Ann Neurol* 50, 121-7.
- 15 26. Kurtzke, J. F. (1983) *Neurology* 33, 1444-52.
27. Liu, X., Bai, X. F., Wen, J., Gao, J.-X., Liu, J., Lu, P., Wang, Y., Zheng, P. & Liu, Y. (2001) *J. Exp. Med.* 194, 1339-1348.
28. Agresti, A. (1990) New York: John Wiley & Sons.
- 20 29. Spielman, R. S. & Ewens, W. J. (1998) *Am J Hum Genet* 62, 450-8.
30. Fleming, T. R. & Harrington, D. P. (1991) *Counting processes & survival analysis* (John Wiley and Sons., New York).
31. Martin, E. R., Monks, S. A., Warren, L. L. & Kaplan, N. L. (2000) *Am J Hum Genet* 67, 146-54.
- 25 32. Englund, P. T. (1993) *Annu Rev Biochem* 62, 121-38.
33. Udenfriend, S. & Kodukula, K. (1995) *Annu Rev Biochem* 64, 563-91.
34. Eisenhaber, B., Bork, P. & Eisenhaber, F. (1998) *Protein Eng* 11, 1155-61.
35. Haines, J. L., Terwedow, H. A., Burgess, K., Pericak-Vance, M. A., Rimmmler, J. B., Martin, E. R., Oksenberg, J. R., Lincoln, R., Zhang, D. Y., Banatao, D. R., Gatto, N., Goodkin, D. E. & Hauser, S. L. (1998) *Hum Mol Genet* 7, 1229-34.
- 30

CLAIMS

What is claimed is:

1. A method for predicting the likelihood that an individual will develop multiple sclerosis, comprising the steps of:

- 5 a) obtaining a nucleic acid sample from an individual to be assessed; and
- b) determining the nucleotide present at the nucleotide position corresponding to position 226 of the native CD24 gene in the individual which sequence corresponds to SEQ ID NO: 1,
- wherein the presence of an thymadine at position 226 indicates that the individual has a greater likelihood of being diagnosed with multiple sclerosis than an individual having a cytosine at that
- 10 position.
2. A method according to claim 1, wherein the individual is an individual at risk for development multiple sclerosis based on the presence of an allelic variant of HLA.
3. A method according to claim 1, wherein the individual exhibits clinical symptoms of multiple sclerosis.
- 15 4. A method according to claim 1, wherein at least one blood relative of the individual has been diagnosed with multiple sclerosis.
5. A method for predicting the likelihood that an individual who has been diagnosed with multiple sclerosis will experience rapid progression of multiple sclerosis, comprising the steps of:
- 20 a) obtaining a nucleic acid sample from an individual to be assessed; and

b) determining the nucleotide present at the nucleotide position corresponding to position 226 of the native CD24 gene in the individual which sequence corresponds to SEQ ID NO: 1,

wherein the presence of an thymadine at position 226 indicates that the individual has a greater likelihood of experiencing rapid progression of multiple sclerosis than an individual diagnosed

5 with multiple sclerosis and having an cytosine at that position.

6. A method of diagnosing or aiding in the diagnosis of multiple sclerosis in an individual comprising

a) obtaining a nucleic acid sample from the individual;

b) determining the HLA genotype of the individual; and

10 c) determining the nucleotide present at nucleotide position 226 of the CD24 gene,

wherein the presence of the HLA-DR2 genotype together with the presence of a thymadine at position 226 of the CD24 gene is indicative that the individual is more likely to develop multiple sclerosis as compared with an individual lacking the HLA-DR2 genotype and having a cytosine at position 226 of the CD24 gene.

15 7. The method of claim 1, wherein the CD24 gene has the nucleotide sequence of SEQ ID NO: 1.

8. A method for predicting the likelihood that an individual will develop multiple sclerosis, comprising the steps of:

a) obtaining a cell sample from an individual to be assessed;

b) determining the level of cell surface expression of CD24 protein on the surface of said cells;

20 and

c) determining a base-line level of cell surface expression of the CD24 protein on control cells,

wherein an increased level of expression of CD24 on the cells isolated from the individual as compared with the control cells indicates that the individual has a thymadine at position 226 of the CD24 gene, and therefore has a greater likelihood of being diagnosed with multiple sclerosis than an individual having a cytosine at that position.

5 9. A method according to claim 8, wherein the cell sample comprises peripheral blood lymphocytes.

10. A method according to claim 8, wherein the cell sample comprises T lymphocytes.

11. A method according to claim 8, wherein the individual is an individual at risk for development multiple sclerosis based on the presence of an allelic variant of HLA.

10 12. A method according to claim 8, wherein the individual exhibits clinical symptoms of multiple sclerosis.

13. A method according to claim 8, wherein at least one blood relative of the individual has been diagnosed with multiple sclerosis.

14. A method for predicting the likelihood that an individual will develop multiple sclerosis,
15 comprising the steps of:

a) obtaining a nucleic acid sample from an individual to be assessed;

b) screening the entire nucleotide sequence encoding the human CD24; and

c) detecting the presence of one ore more polymorphisms of the CD24,

wherein the presence of an thymadine at position 226, and the presence of at least one other
20 variant allele in the polynucleotide encoding CD24 that has been shown to have a positive correlation with increased risk for developing MS based on both population study and on

transmission disequilibrium analysis, indicates that the individual has a greater likelihood of developing multiple sclerosis than an individual having a cytosine at position 226 and lacking any other variant alleles in the polynucleotide encoding CD24 that has been shown to have a positive correlation with increased risk for developing MS based on both population study and

5 on transmission disequilibrium analysis.

Figure A

Human CD24 polynucleotide sequence, SEQUENCE ID NO: 1

(HUCD24)

The human CD24 cDNA sequence

```

5      1 cggttctcca agcaccacgc atcctgctag acgcgccgcg caccgacgga ggggacatgg
      61 gcagagcaat ggtggccagg ctggggctgg ggctgctgct gctggcactg ctctaccca
     121 cgcagattta ttccagtga acaacaactg gaacttcaag taactctcc cagagtactt
     181 ccaactctgg gttggcccca aatccaacta atgccaccac caaggcggct ggtggtgccc
     241 tgcagtcaac agccagtctc ttcgtggtct cactctctct tctgcatctc tactcttaag
10    301 agactcaggc caagaaacgt cttctaaatt tccccatctt ctaaacccaa tccaaatggc
     361 gtctggaagt ccaatgtggc aaggaaaaac aggtcttcat cgaatctact aattccacac
     421 cttttattga cacagaaaat gttgagaatc ccaaatttga ttgatttgaa gaacatgtga
     481 gaggtttgac tagatgatga atgccaatat taaatctgct ggagtttcat gtacaagatg
     541 aaggagaggc aacatccaaa atagttaaga catgatttcc ttgaatgtgg cttgagaaat
15    601 atggacactt aatactacct tgaaaataag aatagaaata aaggatggga ttgtggaatg
     661 gagattcagt tttcattggt tcattaattc tataaggcca taaaacaggc aatataaaaa
     721 gcttccatcg atctatttat atgtacatga gaaggaatcc ccagggtgta ctgtaattcc
     781 tcaacgtatt gtttcgacgg cactaattta atgccgatat actctagatg aatgtttaca
     841 ttgttgagct attgctgttc tcttggaac tgaactcact ttctctctga ggctttggat
20    901 ttgacattgc atttgacct ttaggtagta attgacatgt gccagggcaa tgatgaatga
     961 gaatctaccc cagatccaag catcctgagc aactcttgat tatccatatt gagtcaaatg
    1021 gtaggcattt cctatcacct gtttccattc aacaagagca ctacattctt ttagctaaac
    1081 ggattccaaa gagtagaatt gcattgacca cgactaattt caaatgctt tttattatta
    1141 ttatTTTTTA gacagtctca ctttgctgcc caggccggag tgcagtggtg cgatctcaga
25    1201 tcagtgtacc atttgectcc cgggetcaag cgattctcct gcctcagcct cccaagtagc
    1261 tgggattaca ggcacctgcc accatgcccg gctaattttt gtaattttag tagagacagg

```

Figure A (continued)

1321 gtttcacccat gttgcccagg ctggttttaga actcctgacc tcaggatgatc caccgcgctc
 1381 ggccctcccaa agtgctggga ttacaggctt gagcccccgc gccagccat caaaatgctt
 5 1441 tttatttctg catatgtttg aatactttttt acaattttaa aaaatgatct gttttgaagg
 1501 caaaattgca aatcttgaaa ttaagaaggc aaaatgtaa ggagtcaaac tataaatcaa
 1561 gtatttgga agtgaagact ggaagcta atgcataaat tcacaaactt ttatactctt
 1621 tctgtatata catttttttt ctttaaaaaa caactatgga tcagaatagc aacattttaga
 1681 acactttttg ttatcagtc atatttttag atagttagaa cctggctcta agcctaaaag
 10 1741 tgggcttgat tctgcagtaa atctttttaca actgcctga cacacataaa ctttttttaa
 1801 aatagacact cccgaagtc ttttgtttgt atggtcacac actgatgctt agatgttcca
 1861 gtaatcta atggccacag tagtcttgat gaccaaagtc ctttttttcc atcttttaga
 1921 aactacatgg gaacaaacag atcgaacagt tttgaagcta ctgtgtgtgt gaatgaacac
 1981 tcttgcttta ttccagaatg ctgtacatct attttgatt gtatattgtg gttgtgtatt
 15 2041 tacgctttga ttcataagtaa cttcttatgg aattgatttg cattgaacga caaactgtaa
 2101 ataaaaagaa acggtg

Figure B**Human CD24 polypeptide sequence, SEQ ID NO.:2**

```
5  MGRAMVARLG LGLLLLALLL PTQIYSSETT TGTSSNSSQS TSNSGLAPNP TNATTKAAGG 60
   ALQSTASLFV VSLSLLHLYS
```




Fig. 1




Fig. 2




Fig. 3



Fig. 4



Fig. 5

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/039391

International filing date: 22 November 2004 (22.11.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/525,502
Filing date: 26 November 2003 (26.11.2003)

Date of receipt at the International Bureau: 29 December 2004 (29.12.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse